Highlights • A correct patient risk stratification is of paramount importance for the proper management of economic and human resources. • It's fundamental to prioritize clinical trials evaluating dosing, prophylaxis, and treatment with immunosuppressant in COVID-19 in order to avoid either an overuse and a treatment shortage. • Future controlled studies may highlight in our patients a potential preventive role of immunosuppressant therapies in the development of severe forms of Covid-19. • Despite the overall risk of infection in rheumatic and gastroenterological diseases a conclusive association between these diseases and COVID −19 remains questionable.
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion / Sarzi-Puttini, P; Marotto, D; Antivalle, M; Salaffi, F; Atzeni, F; Maconi, G; Monteleone, G; Rizzardini, G; Antinori, S; Galli, M; Ardizzone, S. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - STAMPA. - 5:102574(2020). [10.1016/j.autrev.2020.102574.]